Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

NCT00479557 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

BIOLOGICAL: ACC-001 + QS-21
BIOLOGICAL: ACC-001
BIOLOGICAL: QS-21
DRUG: Placebo: Phosphate buffered saline

Sponsor

Pfizer

Collaborators

[object Object]